Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Plans IP Law Shake-Up

New Patent Scheme And SPCs Are In The Frame

Executive Summary

European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.

You may also be interested in...



EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods

Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.

EU Reveals Plans For Unitary SPC & Review Of Compulsory Licensing

The EU has announced two separate legal initiatives, one that would improve IP protections, and another that could weaken them in the event of a future health crisis.

EU Reveals Plans For Unitary SPC & Review Of Compulsory Licensing

The EU has announced two separate legal initiatives, one that would improve IP protections, and another that could weaken them in the event of a future health crisis.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel